T1	Age 2 13	54-year-old
T2	Sex 14 19	woman
T3	Disease_disorder 34 39	NSCLC
E1	Disease_disorder:T3 
T4	Detailed_description 25 33	stage IV
R1	MODIFY Arg1:T4 Arg2:E1	
T5	Medication 57 68	carboplatin
E2	Medication:T5 
T6	Medication 73 83	paclitaxel
E3	Medication:T6 
T8	Diagnostic_procedure 110 128	Molecular analysis
E4	Diagnostic_procedure:T8 
T9	Diagnostic_procedure 132 144	tumor tissue
E5	Diagnostic_procedure:T9 
R2	SUB_PROCEDURE Arg1:E5 Arg2:E4	
T10	Detailed_description 149 160	unavailable
R3	MODIFY Arg1:T10 Arg2:E4	
T12	Personal_background 209 214	Asian
T13	History 224 239	smoking history
T14	Severity 216 223	minimal
R4	MODIFY Arg1:T14 Arg2:T13	
T16	Medication 387 396	erlotinib
E7	Medication:T16 
T17	Lab_value 398 404	150 mg
R5	MODIFY Arg1:T17 Arg2:T15	
T18	Detailed_description 362 370	standard
R7	MODIFY Arg1:T18 Arg2:T15	
R8	BEFORE Arg1:E1 Arg2:E2	
*	OVERLAP E2 E3 E4
T19	Coreference 410 421	her disease
E9	Coreference:T19 
T20	Date 433 458	Twenty-eight months later
E10	Date:T20 
T21	Medication 487 496	erlotinib
E11	Medication:T21 
T22	Coreference 517 524	disease
E12	Coreference:T22 
T23	Detailed_description 525 537	systemically
T24	Sign_symptom 4114 4122	survived
E13	Sign_symptom:T24 
T25	Date 4123 4171	14 months following the diagnosis of CNS disease
E14	Date:T25 
T26	Disease_disorder 4160 4171	CNS disease
E15	Disease_disorder:T26 
*	OVERLAP E13 E14
T27	Date 3959 3974	One month later
E16	Date:T27 
T28	Medication 4032 4041	cetixumab
E17	Medication:T28 
T29	Medication 4046 4055	erlotinib
E18	Medication:T29 
T30	Lab_value 4095 4101	100 mg
T31	Dosage 4085 4093;4103 4108	low dose daily
R13	MODIFY Arg1:T30 Arg2:T31	
T33	Dosage 3933 3947	1500 mg weekly
T35	Medication 3948 3957	erlotinib
E19	Medication:T35 
R14	MODIFY Arg1:T33 Arg2:E19	
R16	MODIFY Arg1:T31 Arg2:E18	
A3	TREND E18 DEC
R18	BEFORE Arg1:E19 Arg2:E16	
T36	Disease_disorder 3988 4010	intra-thoracic disease
E20	Disease_disorder:T36 
T37	Detailed_description 3976 3987	progressive
R19	MODIFY Arg1:T37 Arg2:E20	
*	OVERLAP E16 E20
R20	BEFORE Arg1:E20 Arg2:E17	
*	OVERLAP E17 E18
R21	BEFORE Arg1:E18 Arg2:E13	
T38	Diagnostic_procedure 256 265	histology
E21	Diagnostic_procedure:T38 
T39	Detailed_description 241 255	non-small cell
R22	MODIFY Arg1:T39 Arg2:E21	
T40	Coreference 277 288	her disease
E22	Coreference:T40 
R23	IDENTICAL Arg1:E22 Arg2:E1	
A4	POLARITY E4 NEG
T47	History 256 265	histology
T48	Diagnostic_procedure 302 326	EGFR TKI sensitive cells
E23	Diagnostic_procedure:T48 
R24	MODIFY Arg1:E23 Arg2:E22	
R25	BEFORE Arg1:E23 Arg2:E7	
R26	IDENTICAL Arg1:E12 Arg2:E9	
T53	Detailed_description 502 513	progression
R27	MODIFY Arg1:T53 Arg2:E12	
*	OVERLAP E11 E12
T54	Medication 593 615	angiogenesis inhibitor
E24	Medication:T54 
T55	Detailed_description 580 592	experimental
R28	MODIFY Arg1:T55 Arg2:E24	
T56	Medication 631 641	pemetrexed
E25	Medication:T56 
T57	Coreference 654 677	standard dose erlotinib
E26	Coreference:T57 
*	OVERLAP E25 E26
T60	Date 703 718	11 months later
E27	Date:T60 
T61	Coreference 720 731	her disease
E28	Coreference:T61 
R29	IDENTICAL Arg1:E28 Arg2:E12	
T62	Detailed_description 738 748	progressed
R30	MODIFY Arg1:T62 Arg2:E28	
*	OVERLAP E28 E27 E30
R31	BEFORE Arg1:E26 Arg2:E27	
T67	Other_event 473 483	resistance
E29	Other_event:T67 
*	OVERLAP E10 E29
R32	MODIFY Arg1:E11 Arg2:E29	
R33	BEFORE Arg1:E12 Arg2:E24	
R34	BEFORE Arg1:E24 Arg2:E25	
T68	Diagnostic_procedure 773 779	biopsy
E30	Diagnostic_procedure:T68 
T69	Diagnostic_procedure 887 904	Direct sequencing
E31	Diagnostic_procedure:T69 
T70	Diagnostic_procedure 950 954	EGFR
E32	Diagnostic_procedure:T70 
T71	Detailed_description 933 946	kinase domain
R35	MODIFY Arg1:T71 Arg2:E32	
T72	Diagnostic_procedure 968 982	L858R mutation
E33	Diagnostic_procedure:T72 
R36	SUB_PROCEDURE Arg1:E33 Arg2:E32	
R37	SUB_PROCEDURE Arg1:E32 Arg2:E31	
T73	Diagnostic_procedure 1058 1072	T790M mutation
E34	Diagnostic_procedure:T73 
T74	Biological_structure 750 753	DNA
R38	MODIFY Arg1:T74 Arg2:E30	
T75	Disease_disorder 802 808	lesion
E35	Disease_disorder:T75 
T76	Biological_structure 797 801	lung
T77	Detailed_description 785 796	progressing
R39	MODIFY Arg1:T76 Arg2:E35	
R40	MODIFY Arg1:T77 Arg2:E35	
T78	Diagnostic_procedure 867 881	EGFR mutations
E36	Diagnostic_procedure:T78 
T79	Sign_symptom 1150 1159	headaches
E37	Sign_symptom:T79 
T80	Disease_disorder 1207 1217	metastases
E38	Disease_disorder:T80 
T81	Biological_structure 1203 1206	CNS
R41	MODIFY Arg1:T81 Arg2:E38	
A5	POLARITY E38 MAYBE_POS
T82	Diagnostic_procedure 1235 1242	imaging
E39	Diagnostic_procedure:T82 
T83	Lab_value 1226 1234	negative
R42	MODIFY Arg1:T83 Arg2:E39	
A6	POLARITY E39 NEG
T84	Detailed_description 908 919	exons 18â€“21
R43	MODIFY Arg1:T84 Arg2:T71	
T85	Detailed_description 999 1019	EGFR TKI sensitivity
R44	MODIFY Arg1:T85 Arg2:E33	
T86	Detailed_description 1089 1117	acquired EGFR TKI resistance
R45	MODIFY Arg1:T86 Arg2:E34	
T87	Therapeutic_procedure 1270 1285	lumbar puncture
E40	Therapeutic_procedure:T87 
A7	POLARITY E40 NEG
T88	Medication 1309 1321	temozolomide
E41	Medication:T88 
T89	Detailed_description 1301 1308	empiric
R46	MODIFY Arg1:T89 Arg2:E41	
R47	MODIFY Arg1:T23 Arg2:E12	
R50	MODIFY Arg1:E35 Arg2:E30	
T90	Detailed_description 1327 1340	standard dose
T92	Medication 1341 1350	erlotinib
E6	Medication:T92 
T93	Dosage 1352 1364	150 mg daily
T91	Disease_disorder 1379 1390	CNS disease
E42	Disease_disorder:T91 
A8	POLARITY E42 MAYBE_POS
T94	Time 1396 1411	after one cycle
E43	Time:T94 
T95	Sign_symptom 1416 1425	headaches
E44	Sign_symptom:T95 
T96	Lab_value 1426 1434	worsened
R51	MODIFY Arg1:T96 Arg2:E44	
T97	Sign_symptom 1454 1460	nausea
E45	Sign_symptom:T97 
T98	Sign_symptom 1465 1473	vomiting
E46	Sign_symptom:T98 
T99	Disease_disorder 1489 1503	CNS metastases
E47	Disease_disorder:T99 
T100	Diagnostic_procedure 1527 1548	intracranial pressure
E48	Diagnostic_procedure:T100 
T101	Lab_value 1520 1526	raised
R52	MODIFY Arg1:T101 Arg2:E48	
T102	Diagnostic_procedure 1550 1576	Magnetic resonance imaging
E49	Diagnostic_procedure:T102 
T103	Diagnostic_procedure 1577 1582	(MRI)
E50	Diagnostic_procedure:T103 
R53	IDENTICAL Arg1:E50 Arg2:E49	
T104	Biological_structure 1590 1595	brain
T105	Diagnostic_procedure 1637 1649	CSF cytology
E51	Diagnostic_procedure:T105 
R54	MODIFY Arg1:T104 Arg2:E50	
R55	SUB_PROCEDURE Arg1:E51 Arg2:E50	
T106	Disease_disorder 1613 1615	LM
E52	Disease_disorder:T106 
T107	Biological_structure 1685 1688	DNA
T108	Diagnostic_procedure 1673 1683	sequencing
E53	Diagnostic_procedure:T108 
T109	Detailed_description 1666 1672	direct
R56	MODIFY Arg1:T109 Arg2:E53	
T110	Diagnostic_procedure 1694 1703	CSF cells
E54	Diagnostic_procedure:T110 
T111	Diagnostic_procedure 1713 1718	L858R
E55	Diagnostic_procedure:T111 
T112	Diagnostic_procedure 1730 1750	EGFR TKI sensitivity
E56	Diagnostic_procedure:T112 
T113	Diagnostic_procedure 1783 1808	T790M resistance mutation
E57	Diagnostic_procedure:T113 
T114	Diagnostic_procedure 1850 1855	T790M
E58	Diagnostic_procedure:T114 
A9	POLARITY E58 NEG
T115	Lab_value 1860 1868	negative
R57	MODIFY Arg1:T115 Arg2:E58	
A10	POLARITY E56 MAYBE_POS
A11	POLARITY E57 MAYBE_NEG
T116	Coreference 1872 1883	this sample
E59	Coreference:T116 
R58	IDENTICAL Arg1:E59 Arg2:E54	
T117	Diagnostic_procedure 1948 1953	assay
E60	Diagnostic_procedure:T117 
T118	Lab_value 1900 1914	more sensitive
T119	Detailed_description 1915 1937	fluorescence detection
T120	Detailed_description 1938 1947	PCR-based
R59	MODIFY Arg1:T120 Arg2:E60	
R60	MODIFY Arg1:T119 Arg2:E60	
R61	MODIFY Arg1:T118 Arg2:E60	
T121	Diagnostic_procedure 1980 2024	PCR restriction fragment length polymorphism
E61	Diagnostic_procedure:T121 
T122	Coreference 2038 2068	the specific missense mutation
E62	Coreference:T122 
T123	Coreference 2120 2131	That result
E63	Coreference:T123 
A12	POLARITY E63 NEG
T124	Lab_value 2141 2149	negative
R62	MODIFY Arg1:T124 Arg2:E63	
T125	Diagnostic_procedure 2163 2177	wild type peak
E64	Diagnostic_procedure:T125 
A13	POLARITY E64 POS
R63	IDENTICAL Arg1:E63 Arg2:E60	
R64	SUB_PROCEDURE Arg1:E62 Arg2:E61	
R65	IDENTICAL Arg1:E62 Arg2:E57	
T155	Diagnostic_procedure 3025 3049	Pharmacokinetic analysis
E76	Diagnostic_procedure:T155 
T156	Biological_structure 3053 3056	CSF
R81	MODIFY Arg1:T156 Arg2:E76	
T157	Subject 3062 3077	another patient
T158	Disease_disorder 3089 3091	LM
E77	Disease_disorder:T158 
T159	Disease_disorder 3083 3088	NSCLC
E78	Disease_disorder:T159 
R82	MODIFY Arg1:E78 Arg2:E77	
T160	Dosage 3117 3124;3135 3141	1500 mg weekly
T162	Medication 3125 3134	erlotinib
E79	Medication:T162 
R88	MODIFY Arg1:T160 Arg2:E79	
R90	MODIFY Arg1:T93 Arg2:T90	
R91	MODIFY Arg1:T90 Arg2:E6	
T165	Lab_value 3186 3195	11,300 nM
T166	Diagnostic_procedure 3157 3182	peak plasma concentration
E80	Diagnostic_procedure:T166 
T169	Lab_value 3235 3241	130 nM
T170	Diagnostic_procedure 3214 3231	CSF concentration
E81	Diagnostic_procedure:T170 
R75	MODIFY Arg1:T169 Arg2:E81	
R92	MODIFY Arg1:T165 Arg2:E80	
T172	Detailed_description 3333 3351	exceeding the IC50
R93	MODIFY Arg1:T172 Arg2:T169	
T178	Dosage 3458 3474	high-dose weekly
T179	Medication 3475 3484	erlotinib
E87	Medication:T179 
T180	Lab_value 3488 3495	1000 mg
T181	Lab_value 3501 3508	1200 mg
R96	MODIFY Arg1:T178 Arg2:E87	
R98	MODIFY Arg1:T180 Arg2:T178	
R99	MODIFY Arg1:T181 Arg2:T178	
R100	MODIFY Arg1:T178 Arg2:E87	
T182	Sign_symptom 3521 3527	nausea
E88	Sign_symptom:T182 
T183	Detailed_description 3510 3520	persistent
R102	MODIFY Arg1:T183 Arg2:E88	
T184	Diagnostic_procedure 3552 3576	Pharmacokinetic analysis
E89	Diagnostic_procedure:T184 
A15	POLARITY E89 NEG
T186	Disease_disorder 3758 3771	hydrocephalus
E91	Disease_disorder:T186 
T187	Sign_symptom 3787 3795	symptoms
E92	Sign_symptom:T187 
T188	Detailed_description 3776 3786	persistent
R104	MODIFY Arg1:T188 Arg2:E92	
T189	Diagnostic_procedure 3819 3840	intracranial pressure
E93	Diagnostic_procedure:T189 
T190	Therapeutic_procedure 3850 3858	VP shunt
E94	Therapeutic_procedure:T190 
T191	Lab_value 3809 3818	increased
R105	MODIFY Arg1:T191 Arg2:E93	
T192	Therapeutic_procedure 3875 3892	radiation therapy
E95	Therapeutic_procedure:T192 
T193	Biological_structure 3863 3874	whole-brain
R106	MODIFY Arg1:T193 Arg2:E95	
T7	Detailed_description 84 108	without disease response
R9	MODIFY Arg1:T7 Arg2:E2	
R10	MODIFY Arg1:T7 Arg2:E3	
A2	POLARITY E23 MAYBE_POS
*	OVERLAP E5 E23
R11	IDENTICAL Arg1:E9 Arg2:E22	
R12	BEFORE Arg1:E7 Arg2:E9	
T11	Detailed_description 422 431	responded
R107	MODIFY Arg1:T11 Arg2:E9	
R108	BEFORE Arg1:E9 Arg2:E10	
#1	AnnotatorNotes E29	Not sure how to label drug resistance 
R109	SUB_PROCEDURE Arg1:E36 Arg2:E30	
R110	SUB_PROCEDURE Arg1:E31 Arg2:E36	
R111	SUB_PROCEDURE Arg1:E34 Arg2:E8	
T41	Coreference 1033 1035	It
E8	Coreference:T41 
R112	IDENTICAL Arg1:E8 Arg2:E31	
*	OVERLAP E34 E37 E38 E39 E40 E41 E6 E42
R113	BEFORE Arg1:E42 Arg2:E43	
*	OVERLAP E43 E44 E45 E46 E47
A1	POLARITY E47 MAYBE_POS
R114	MODIFY Arg1:E48 Arg2:E47	
*	OVERLAP E48 E49
R115	MODIFY Arg1:E52 Arg2:E50	
R116	MODIFY Arg1:E52 Arg2:E51	
*	OVERLAP E51 E53
R117	MODIFY Arg1:T107 Arg2:E54	
R118	SUB_PROCEDURE Arg1:E54 Arg2:E53	
R119	SUB_PROCEDURE Arg1:E55 Arg2:E54	
R120	SUB_PROCEDURE Arg1:E56 Arg2:E55	
R121	SUB_PROCEDURE Arg1:E57 Arg2:E54	
*	OVERLAP E57 E58 E60
R122	SUB_PROCEDURE Arg1:E61 Arg2:E60	
*	OVERLAP E62 E63
R123	SUB_PROCEDURE Arg1:E64 Arg2:E63	
R66	MODIFY Arg1:T157 Arg2:E76	
R67	MODIFY Arg1:E77 Arg2:T157	
*	OVERLAP E77 E79 E80 E81
*	OVERLAP E64 E76
R68	BEFORE Arg1:E81 Arg2:E87	
*	OVERLAP E87 E88 E89
T42	Date 3613 3626	After 1 month
E65	Date:T42 
R69	BEFORE Arg1:E89 Arg2:E65	
T43	Diagnostic_procedure 3684 3687	MRI
E66	Diagnostic_procedure:T43 
T44	Biological_structure 3678 3683	brain
R70	MODIFY Arg1:T44 Arg2:E66	
T45	Date 3701 3715	after 2 months
E67	Date:T45 
T46	Biological_structure 3723 3735	cauda equina
R71	BEFORE Arg1:E66 Arg2:E67	
T49	Disease_disorder 3672 3674	LM
E68	Disease_disorder:T49 
T50	Diagnostic_procedure 3639 3668	partial radiographic response
E69	Diagnostic_procedure:T50 
R72	MODIFY Arg1:E68 Arg2:E69	
*	OVERLAP E65 E69
R73	SUB_PROCEDURE Arg1:E69 Arg2:E66	
*	OVERLAP E67 E91 E66 E92 E93
R74	MODIFY Arg1:T46 Arg2:E66	
R76	BEFORE Arg1:E93 Arg2:E94	
*	OVERLAP E94 E95
R77	BEFORE Arg1:E95 Arg2:E19	
T15	Dosage 371 383	daily dosing
R6	MODIFY Arg1:T15 Arg2:E7	
R48	IDENTICAL Arg1:E26 Arg2:E7	
